Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy - sprookjes - yvandenbroek - TriplyDB

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

http://www.wikidata.org/entity/Q28177632

about

sameAs

Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid Drug treatment for spinal muscular atrophy types II and III Drug treatment for spinal muscular atrophy types II and III Drug treatment for spinal muscular atrophy types II and III SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR Clinical and experimental applications of sodium phenylbutyrate Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy Spinal muscular atrophy: from gene discovery to clinical trials Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy Alternative splicing for diseases, cancers, drugs, and databases Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy.Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration The promise and perils of HDAC inhibitors in neurodegeneration A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients Phase II open label study of valproic acid in spinal muscular atrophy Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.Genetically modified pig models for neurodegenerative disorders.A novel cell immunoassay to measure survival of motor neurons protein in blood cells Development of histone deacetylase inhibitors as therapeutics for neurological disease Pretreatment with Sodium Phenylbutyrate Alleviates Cerebral Ischemia/Reperfusion Injury by Upregulating DJ-1 Protein.Squamocin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells.Splicing of the Survival Motor Neuron genes and implications for treatment of SMA Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay.A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo.Therapeutic developments in spinal muscular atrophy.Drug discovery and development for spinal muscular atrophy: lessons from screening approaches and future challenges for clinical development.Therapeutic strategies for the treatment of spinal muscular atrophy.VPA response in SMA is suppressed by the fatty acid translocase CD36.SMN-inducing compounds for the treatment of spinal muscular atrophy.Activation of the stress proteome as a mechanism for small molecule therapeutics.New perspectives of valproic acid in clinical practice.4-Phenylbutyrate attenuates the ER stress response and cyclic AMP accumulation in DYT1 dystonia cell models.

P2860

Q21261395-B8254CC0-5AC6-4FB8-BD44-E32B3A8E2C45 Q24200270-E3D79A2A-3CDB-4EE2-87F4-CCD8A0EB5C2D Q24234414-567456DE-AB1D-41ED-B2E1-F8DE25CB8321 Q24241759-F7001604-ADE4-4145-AEFB-A5C00F1AB65E Q24599124-26872F7E-D8AA-4D15-9669-84AC014832A8 Q24613511-3C929615-97E1-4864-B456-B8F998458DB8 Q24655533-98AD71F3-0972-4228-B31F-1EA5975CD2C9 Q26752798-F92392C2-D9CB-4061-849D-417BB9242E39 Q26824894-6FDFECAF-F570-4A09-83F2-776DAA26F7C8 Q26828876-7B86CA6E-2884-434E-BFFF-90050A9C10A0 Q26852848-4231B334-E7BE-47DA-8DA1-506D93BD20B6 Q26864605-D0D1C7B0-9227-4C5E-9D70-B5DEB98C1531 Q27328843-959A1281-2859-475C-9A8A-6D29A91D78E3 Q28080593-24AB7A31-5399-4E0A-A22A-1CA7D886B1E9 Q28087539-E64A061D-0EE2-4E08-AA3E-0A60369FBCD1 Q28243807-E712388E-967F-4DB4-AE05-A90389259100 Q28271235-4B3B92B9-71DA-46AE-A5D6-D03B535A5B31 Q28289793-EA24D8C0-B5D8-4E5D-9D48-02E38E644F18 Q28291453-025AADDD-34EC-4B70-B55A-DC776458B206 Q28475498-F66CBDD4-3776-49AA-B779-2A16CD5A9B13 Q28740896-282D5CB7-79BB-4B93-A0BE-50CB510D14F5 Q30492560-9F59AAAF-58B6-477E-9D8C-5CD01F9D06BC Q30493891-FB85AA5D-F9B0-4EEC-91BA-6DBC8A7A4673 Q30743508-52096CAE-ECD4-4637-ADB9-299B3706A526 Q31002975-3F33DDF7-640C-45F5-B098-3346E34FCF82 Q33232855-2A05A932-E9CF-41C3-AC29-C906C72AB773 Q33670661-1BE52E3D-07F9-4ACF-9689-FC332B9E415E Q33780795-656A2FE5-12FD-4E68-9ECE-51B935B19FF2 Q33813964-33C78A4E-0D4B-4B29-A337-7550646BF327 Q34065993-017D38F0-9637-4262-84CB-BD9EC2BAD93F Q34123129-70E97E82-485B-4C61-BFD2-D62C1D6F2192 Q34132150-4F315AB5-15F4-4447-B368-249C4224071B Q34156272-849216A9-779B-49ED-9405-0009E9C3F063 Q34172502-EC1F8EBC-F822-4EA8-B202-46D0C23DABC8 Q34296140-CE687D8B-50EB-4A77-BC05-F93BD4CB7A5A Q34306857-96954954-8112-42F1-B255-40180EC63AF4 Q34312156-8E90A045-C337-4E3B-92D3-A6E6575F0BD1 Q34323595-85CC3814-A30F-482E-882C-D1C98722F948 Q34380256-99FB419A-6B87-4F1B-8714-63CF5FE3DDAC Q34472800-4DABAA46-42EB-4341-841B-51557E0DC67A

P2860

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

http://www.wikidata.org/entity/Q28177632

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@ast

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@en

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@nl

type

label

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@ast

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@en

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@nl

prefLabel

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@ast

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@en

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@nl

P1433

Q28177632-DF96635A-A17E-4B77-9B80-E8EF870AE8FF

P1476

Q28177632-0D98EF5D-0776-4984-B5AD-0C486BEEECCA

P2093

Q28177632-00161E43-A41D-4EA7-B49E-4D6312BF5480

Q28177632-03819BDF-25C4-42D0-99AD-039DDE524041

Q28177632-08B836B2-13CC-4F31-92BB-FF408AEA5B00

Q28177632-10F1EED8-5DBC-47D4-B510-BBCC809ABAF2

Q28177632-38B67E29-0A87-448A-889B-1AC16E2459C6

Q28177632-4974E3E8-7174-492A-9101-953DD524E86F

Q28177632-5E1E05F6-D1B3-4F05-BDD6-66606AED7388

Q28177632-64B2221A-DF25-46A9-98F5-5914CA596A09

Q28177632-6FCCEE42-007A-4BD4-8518-9396208750CF

Q28177632-F6B0D2D1-1177-4806-8F7B-2961F0E7DEDA

P2860

Q28177632-1342A1CB-E979-42FF-B5BB-358B6349BB59

Q28177632-14CED73E-BD84-4C6A-8224-E0A4BE8C229D

Q28177632-217D86C1-E6BE-443E-BE69-723BC3D47848

Q28177632-25B0C1D0-EE05-41CA-966D-E453192E1FDD

Q28177632-2F49B78D-8B8F-483C-9F25-C4CB1573A71B

Q28177632-3B0C4396-E9EE-48FF-A925-0B8C6EF0440B

Q28177632-716F0543-D1D3-4960-B386-A261BE58B50A

Q28177632-76FA41EC-3976-4F64-97D8-2403DB5007DC

Q28177632-A02B6F22-4B88-4CCA-A593-D06AA3ABB47F

Q28177632-A394B638-2C73-475A-9504-3D0096BD2160

P2888

Q28177632-23E11CA0-AE54-40ED-B8F4-F1CB901FFA0A

P304

Q28177632-7CEBDD12-1B59-4612-BBFD-F93ED131D9DB

P31

Q28177632-B7FA1D59-740B-42C5-8E52-F65CF82B766C

P3181

Q28177632-F9913571-355E-4913-8F42-58CA3A76BFC2

P356

Q28177632-7CBCAA08-C2DC-4DEF-BE12-4037BD04D429

P407

Q28177632-47BA6429-2BE0-40C1-B3BF-CE904A9C84C6

P433

Q28177632-8F5AFAFA-2616-4491-81A0-F02B476804F5

P478

Q28177632-ED5634FB-20BD-4445-AB9A-32F85C3A0592

P50

Q28177632-183DD47B-B30A-4B02-82FE-E46DC853BB38

P577

Q28177632-0A45D336-1069-40DF-A9DE-0DCE083D444E

P5875

Q28177632-7A7E8EF3-3562-4009-A83B-974F2A9C4E21

P698

Q28177632-EBEB779F-0B31-4104-99CB-B03BDD912189

P921

Q28177632-32AF496C-1428-412D-916A-AD07C2074C3C

P3181

P356

SJ.EJHG.5201102

P1433

European Journal of Human Genetics

P1476

Phenylbutyrate increases SMN e ...... ent of spinal muscular atrophy

@en

P2093

Alma Boninsegna

http://www.w3.org/2001/XMLSchema#string

Antonella Pini

http://www.w3.org/2001/XMLSchema#string

Carla Angelozzi

http://www.w3.org/2001/XMLSchema#string

Catia Andreassi

http://www.w3.org/2001/XMLSchema#string

Christina Brahe

http://www.w3.org/2001/XMLSchema#string

Eleonora De Vincenzi

http://www.w3.org/2001/XMLSchema#string

Francesco D Tiziano

http://www.w3.org/2001/XMLSchema#string

Giovanni Neri

http://www.w3.org/2001/XMLSchema#string

Marcello Villanova

http://www.w3.org/2001/XMLSchema#string

Tiziana Vitali

http://www.w3.org/2001/XMLSchema#string

P2860

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

Identification and characterization of a spinal muscular atrophy-determining gene

A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy

A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

Treatment of spinal muscular atrophy by sodium butyrate.

Copies of the survival motor neuron gene in spinal muscular atrophy: the more, the better.

Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

The survival motor neuron protein in spinal muscular atrophy.

Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number

Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy.

P2888

sj.ejhg.5201102

P304

59-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5081568

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.EJHG.5201102

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9050441

http://www.w3.org/2001/XMLSchema#string

P698

14560316

http://www.w3.org/2001/XMLSchema#string

P921

spinal muscular atrophy